Ozempic Is Renewed: a New Dose for Adults with Type 2 Diabetes Arrives in Spain
4 Articles
4 Articles
The pharmaceutical company Novo has announced that it is already available in Spain, under medical prescription and funded by the National Health System, a new presentation of Ozempic (subcutaneous saemaglutide) of 2 mg weekly for the treatment of adults with type 2 diabetes mellitus. The new presentation provides a reduction of up to 2.2% in glycated hemoglobin (HbA1c) -a blood test that measures the average glucose (sugar) in the blood during …
The Spanish subsidiary of the Danish multinational Novo has been approved for funding by the National Health System of Ozempic -subcutaneous semaglutide - at the dose of 2 mg under medical prescription for the treatment of adults with type 2 diabetes. According to the company's sources, the new presentation -which doubles the higher dose financed so far for this indication - provides a reduction of up to 2.2% in glycated haemoglobin (HbA1c), as …
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium



